These data corroborate previously published phase I studies evaluating combinations of DNMT inhibitors and HDAC inhibitors in advanced solid tumors and lung cancer and the study of this combination in advanced breast cancer reported concurrently to this study. The gene discussed is DNMT1; the disease is breast carcinoma.